Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Recruiting Not applicable Interventional

CardiAMP Heart Failure II Trial for Patients With Ischemic Heart Failure With Reduced Ejection Fraction

ClinicalTrials.gov ID: NCT06258447

Public ClinicalTrials.gov record NCT06258447. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 7, 2026, 2:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Randomized Controlled Pivotal Trial of Autologous Bone Marrow Mononuclear Cells Using the CardiAMP Cell Therapy System in Patients With Ischemic Heart Failure II Trial

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Concentrated autologous bone marrow mononuclear cells (ABM MNC) contain potentially therapeutic cell factors and past studies support therapeutic benefit to patients with cardiac diseases of acute myocardial infarction, ischemia, and heart failure when utilized as this study is designed. The purpose of the study is to determine the safety and efficacy of CardiAMP cell therapy system in patients with ischemic heart failure. It is a prospective, multi-center, randomized, controlled, patient and evaluator-blinded study comparing treatment with the CardiAMP cell therapy system to a control procedure with diagnostic catheterization.

Study identification

NCT ID
NCT06258447
Recruitment status
Recruiting
Study type
Interventional
Phase
Not applicable
Lead sponsor
BioCardia, Inc.
Industry
Enrollment
250 participants

Conditions and interventions

Eligibility (public fields only)

Age range
21 Years to 90 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 31, 2024
Primary completion
Mar 31, 2027
Completion
Mar 31, 2029
Last update posted
Feb 8, 2026

2024 – 2029

United States locations

U.S. sites
5
U.S. states
5
U.S. cities
5
Facility City State ZIP Site status
Morton Plant Hospital - BayCare Clearwater Florida 33756 Recruiting
Emory University Atlanta Georgia 30322 Recruiting
Henry Ford Hospital Detroit Michigan 48202 Recruiting
Cleveland Clinic Cleveland Ohio 44195 Withdrawn
University of Wisconsin-Division of Cardiovascular Medicine Madison Wisconsin 53792 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06258447, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 8, 2026 · Synced Sep 7, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06258447 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →